Real World Evidence in Medical Cannabis Research

Abstract

Background Whilst access to cannabis-based medicinal products (CBMPs) has increased globally subject to relaxation of scheduling laws globally, one of the main barriers to appropriate patient access remains a paucity of high-quality evidence surrounding their clinical effects. Discussion Whilst randomised controlled trials (RCTs) remain the gold-standard for clinical evaluation, there are notable barriers to their implementation. Development of CBMPs requires novel approaches of evidence collection to address these challenges. Real world evidence (RWE) presents a solution to not only both provide immediate impact on clinical care, but also inform well-conducted RCTs. RWE is defined as evidence derived from health data sourced from non-interventional studies, registries, electronic health records and insurance data. Currently it is used mostly to monitor post-approval safety requirements allowing for long-term pharmacovigilance. However, RWE has the potential to be used in conjunction or as an extension to RCTs to both broaden and streamline the process of evidence generation. Conclusion Novel approaches of data collection and analysis will be integral to improving clinical evidence on CBMPs. RWE can be used in conjunction or as an extension to RCTs to increase the speed of evidence generation, as well as reduce costs. Currently, there is an abundance of potential data however, whilst a number of platforms now exist to capture real world data it is important the right tools and analysis are utilised to unlock potential insights from these.

Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years

“…These datasets are accessible and provide a unique repository of detailed patient-level information around MC approvals that covers almost the entire population of Australian MC patients. It is the largest known dataset of its kind with few other countries/regions systematically capturing approvals in this way (see Banerjee et al, 2022 ).…”

Exploring the Efficacy and Safety of Cannabis in the Management of Fibromyalgia

“…Additionally, 50% stopped taking any other medications for fibromyalgia [42]. The review of Banerjee et al supported these findings [43]. The review by Gonen and Amital [44] discussed that chronic pain including FM is common component in all rheumatoid diseases, and does not respond well to traditional medications.…”

Medical Cannabis: Toward a New Policy and Health Model for an Ancient Medicine

“…Real-world evidence, including PROs [i.e., where health status is reported directly by the patient, without interpretation by a clinician or anyone else ( 36 )], is now building up to a pattern of evidence, emphasizing the effectiveness of using medical cannabis to treat pain syndromes as well as various psychiatric conditions ( 3 ). Real-world evidence can be used to complement RCT or to serve as a precursor to them in order to increase the speed at which evidence is generated, and to reduce costs ( 5 ). For instance, emulating randomized trials from large observational databases and statistical methods to account for bias ( 37 ) hold great promise for assessing cannabis' effectiveness ( 38 , 39 ).…”

“…The reason for this lies in the large variation in cannabis material as a plant ( 3 , 4 ). Real-word data on the medical use of cannabis could be of benefit to patients worldwide, healthcare professionals, policymakers, and researchers ( 3 , 5 , 6 ). In this article, we discuss these points and propose that the collection of patient-reported outcomes (PROs) could be a cornerstone of a medical cannabis policy.…”